Key facts
- Beauty companies are developing treatments for 'Ozempic face,' a concern linked to rapid weight loss from obesity drugs.
- The global obesity drug market could reach $150 billion in annual sales by 2030.
- Revenue from treatments for skin laxity and facial volume loss is projected to grow from $700 million to $2 billion in five years.
- Galderma, L'Oreal, and Natura are actively testing and developing products for this market.
- Experts note that while some skincare products can help appearance, they cannot fully restore lost facial volume.
Swiss skincare firm Galderma, Brazilian cosmetics group Natura and beauty giant L'Oreal are developing treatments to address facial sagging and volume loss, a concern emerging from the widespread use of obesity drugs. The phenomenon, dubbed 'Ozempic face,' is linked to rapid weight loss experienced by users of GLP-1 medications like Novo Nordisk's Ozempic and Eli Lilly's Zepbound.
Experts note that while the drugs mimic hormones to promote fullness, the resulting rapid weight reduction can lead to loose skin and facial volume depletion. Pfizer estimates the obesity drug market could reach $150 billion annually by 2030, creating a significant opportunity for aesthetic companies. Boston Consulting Group projects revenue from these clinical treatments to grow from $700 million to $2 billion over the next five years.
Galderma is evaluating existing treatments for skin changes associated with GLP-1 drugs, while L'Oreal and Natura are conducting separate studies and developing new products. However, some specialists caution that topical skincare products have limitations in fully restoring lost facial volume, with injectables like fillers being more effective for deeper tissue restoration.